First-in-human study of ODM-212 for advanced solid tumors
Part of Cancer clinical trials.
This study tests an experimental drug called ODM-212 for people with advanced solid tumors that have not responded to standard treatments. It may be especially relevant if your tumor has changes in the Hippo pathway (certain genes like NF2 or YAP/TAZ).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be a specific type listed in the study (like mesothelioma, certain lung cancers, colorectal, etc.) or have a particular genetic change (NF2, LATS1/2, YAP/TAZ).
- You must have tried standard treatments that no longer work or aren't suitable for you.
- You need to be in generally good health (able to care for yourself, ECOG 0-1) and have a life expectancy of more than 12 weeks.
- You cannot have had certain other cancers in the last 2 years, recent chemotherapy, or major surgery recently.
- Your heart, kidney, liver, and blood counts must be within safe ranges as tested by the study team.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
This trial is testing a new drug called HDM2020 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new drug, HDM2012, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for gastric and colorectal cancers.
This trial tests a new drug, HDM2005, in people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective for tumors that show a specific marker called ROR1.
This study tests an experimental drug called BGM-2121 for people with advanced solid tumors that have not responded to or stopped responding to standard treatments. The goal is to see if the drug is safe and if it can shrink tumors.
This trial tests a new drug called HDM2017 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects tumors.
Hear when a new Solid Tumours trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.